Understanding how antibodies against SARS-CoV-2 work and their future effectiveness
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies
This study is looking at how well certain antibodies in your body fight against COVID-19 and its different strains, and it’s for people who have had the virus or received the vaccine, as your blood samples can help researchers find ways to make vaccines and treatments even better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10682525 on NIH RePORTER |
What this research studies
This research investigates the origins and long-term effectiveness of neutralizing antibodies that target the receptor binding domain (RBD) of the SARS-CoV-2 virus. By analyzing how these antibodies respond to various strains and variants of the virus, the study aims to uncover mechanisms that could enhance immunity against COVID-19. The approach includes examining immune responses in individuals who have been infected or vaccinated, providing insights into how to improve current vaccines and therapies. Patients may be involved in providing blood samples to help researchers understand antibody responses better.
Who could benefit from this research
Good fit: Ideal candidates for participation include individuals who have been infected with SARS-CoV-2 or have received a COVID-19 vaccine.
Not a fit: Patients who have not been exposed to SARS-CoV-2 or have not received a COVID-19 vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccines and treatments that offer better protection against COVID-19 and its variants.
How similar studies have performed: Previous research has shown promise in understanding antibody responses to other viruses, suggesting that this approach could yield valuable insights for COVID-19.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Kobie, James J — University of Alabama at Birmingham
- Study coordinator: Kobie, James J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.